Corcept Therapeutics Inc
NASDAQ:CORT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of 
Corcept Therapeutics Inc (CORT) under the Base Case is USD per share.
Compared with the current market price of 73.71 USD, the stock appears .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
What one share is worth in the bear, base and bull cases.
Create a free account · No card needed
Do our valuations actually work? See backtest results .
Intrinsic value next to the price over the past 5 years, and what happened after valuations like today’s.
Create a free account · No card needed
Fundamental Analysis
What Corcept Therapeutics Does
Corcept Therapeutics is a specialty drug company focused on medicines that block the effects of cortisol, a hormone the body makes naturally. Its main commercial product is Korlym, a prescription drug used to treat certain patients with endogenous Cushing’s syndrome, a serious disorder caused by too much cortisol. The company also develops related cortisol-modulating drugs for other medical uses.
- Headquarters
- United States of America US
- Employees
- 730
- IPO date
- Apr 15, 2004
Corcept Therapeutics has a wide economic moat
Patents covering relacorilant and its use in ovarian cancer make it harder for rivals to copy Corcept’s approved Lifyorli treatment. FDA approval lets Corcept sell it for a defined group of patients, giving the company a protected treatment option in that market.
Read the full moat analysis
Revenue & Expenses Breakdown
Corcept Therapeutics Inc
Earnings Waterfall
Corcept Therapeutics Inc
What is the Intrinsic Value of one CORT stock?
The intrinsic value for Corcept Therapeutics Inc (CORT) under the Base Case is USD.
Is CORT stock undervalued or overvalued?
Compared with the current market price of 73.71 USD, the stock appears .
